Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.30
-0.4800-3.25%
Post-market: 14.350.0500+0.35%19:30 EDT
Volume:969.16K
Turnover:14.04M
Market Cap:1.22B
PE:-8.19
High:15.00
Open:14.80
Low:14.17
Close:14.78
52wk High:25.77
52wk Low:4.52
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.07
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.50
PE(LYR):-30.75

Loading ...

Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)

Simply Wall St.
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)

TIPRANKS
·
Aug 13

Monte Rosa Therapeutics is Maintained at Overweight by Wells Fargo

Dow Jones
·
Aug 07

Gyre Therapeutics Q2 Revenue Beats Estimates on Higher Etuary Sales Volumes

Reuters
·
Aug 07

Relay Therapeutics Q2 Revenue Misses Estimates on Higher R&D Expenses; Net Loss Widens

Reuters
·
Aug 07

Monte Rosa Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate

Benzinga Earnings
·
Aug 06

Monte Rosa Publishes Corporate Presentation on Targeted Protein Degradation Pipeline and Molecular Glue Degraders

Reuters
·
Aug 06

Monte Rosa Activates Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in Metastatic Prostate Cancer

Reuters
·
Aug 06

Monte Rosa Q2 FY26 Net Loss Widens to $43.4 Million; Revenue Falls 61.3% to $9 Million

Reuters
·
Aug 06

Monte Rosa Therapeutics Q2 Operating Expenses USD 58.098 Million

THOMSON REUTERS
·
Aug 06

Monte Rosa’s MODeFIRe-1 Trial Pushes GLUE Into a Key Mid-Stage Prostate Cancer Test

TIPRANKS
·
Aug 05

Monte Rosa Therapeutics is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 03

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss

TIPRANKS
·
Aug 01

Monte Rosa Tumbles on Read-through from Novo's Cardiovascular Trial Failure

Reuters
·
Jul 31

Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating

MT Newswires Live
·
Jul 31

Have Insiders Sold Monte Rosa Therapeutics Shares Recently?

Simply Wall St.
·
Jul 20

Monte Rosa CEO Markus Warmuth Sells 9,500 Shares Worth $220,219.55

Reuters
·
Jul 18

Monte Rosa COO Jennifer Champoux Disposes of 4,351 Common Shares Worth $101,707.28

Reuters
·
Jul 17